Sanofi drops sharply on poor quarter
This article was originally published in Scrip
Sanofi's earnings fell 24% in a "frustrating" second quarter, according CEO Christopher Viehbacher, resulting in the French pharma cutting its 2013 forecast guidance. Sanofi was hit by the residual impact of the patent cliff, an inventory problem in Brazil, and currency fluctuations.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.